--- title: "Sigrid Therapeutics aims to ward off Type 2 diabetes with an edible, powdered medical device" type: "Media Coverage" date: "2019-10-24" updated: "2026-10-09" description: "Conor Hale identifies SiPore® innovative mode of action, an oversubscribed funding round and Sigrid Therapeutic’s promising path ahead." url: "https://sipore.com/insights/sigrid-therapeutics-aims-to-ward-off-type-2-diabetes-with-an-edible-powdered-med" canonical: "https://sipore.com/insights/sigrid-therapeutics-aims-to-ward-off-type-2-diabetes-with-an-edible-powdered-med" markdown_url: "https://sipore.com/insights/sigrid-therapeutics-aims-to-ward-off-type-2-diabetes-with-an-edible-powdered-med.md" site: "SiPore" publisher: "SiPore Technologies (Sigrid Therapeutics AB)" contact: "contact@sipore.com" language: "en" outlet: "Fierce Biotech" original_url: "https://www.fiercebiotech.com/medtech/sigrid-therapeutics-aims-to-ward-off-type-2-diabetes-edible-powdered-medical-device" --- # Sigrid Therapeutics aims to ward off Type 2 diabetes with an edible, powdered medical device *Media Coverage · Oct 24, 2019 · Fierce Biotech* > Conor Hale identifies SiPore® innovative mode of action, an oversubscribed funding round and Sigrid Therapeutic’s promising path ahead. ## Coverage - **Outlet:** Fierce Biotech - **Original article:** [Fierce Biotech](https://www.fiercebiotech.com/medtech/sigrid-therapeutics-aims-to-ward-off-type-2-diabetes-edible-powdered-medical-device) Sigrid Therapeutics is developing SiPore15, an edible silica powder designed to help reduce blood sugar levels in people with prediabetes and newly diagnosed, untreated Type 2 diabetes. ## How SiPore15 works Technically a medical device—or even a “therapeutic material”—the tasteless and odorless powder is not absorbed by the body. The porous silica particles mechanically separate digestive enzymes from pieces of food, gently slowing gastral processes. They are then eliminated from the body normally. ## Proof-of-concept results SiPore15 recently showed a 1.4 mmol/mol mean reduction in HbA1c levels in a proof-of-concept study with no increased safety risks or serious adverse events, according to the company. The open-label, single-arm [trial](https://www.clinicaltrials.gov/ct2/show/NCT03823027) enrolled 43 obese or overweight participants for three months of treatment. Served in foil packets and mixed with water before the three main meals of the day, doses were increased from one gram per meal to the full dose of three grams per meal. “The reduction achieved in HbA1c with SiPore15 after 12 weeks of administration was similar to that of large, years-long studies with metformin, the only drug considered for treatment of selected prediabetes patients by the American Diabetes Association,” Sigrid Therapeutics CEO Sana Alajmovic said in a [statement](https://www.sigridthx.com/2019/09/26/sigrid-therapeutics-takes-another-step-towards-a-treatment-for-prevention-of-type-2-diabetes/). The company said it plans to submit the full results for publication and presentation at a scientific conference. “Importantly, SiPore15 was well tolerated, which is a significant competitive advantage over systemically acting drugs,” Alajmovic added. “The 12-week follow up period of the study is ongoing and we look forward to reporting final results by the end of this year, as we are working towards obtaining device clearance to market SiPore15 in the EU.” ## Funding and future indications In September, the Stockholm-based company raised $1.6 million in an equity financing round led by Joyance Partners and Pär Gellerfors, co-founder of the immunotherapy-focused BioArctic, who sits on the company’s board of directors. They were joined by Swedish investment firm Axilium Capital, as well as Karsten Inde, founder of the private care service Team Olivia. The [oversubscribed round](https://www.sigridthx.com/2019/09/05/stockholm-based-technology-startup-sigrid-therapeutics-developing-sipore15tm-a-breakthrough-device-to-lower-blood-sugar-levels-closes-oversubscribed-round-of-1-6m-bringing-total-pre-laun/) brought Sigrid Therapeutics’ total funding up to $9 million. In future indications, the company aims to tweak the specific properties of the silica particles to engage different diseases, potentially including gestational and pediatric Type 2 diabetes, nonalcoholic steatohepatitis, and the modulation of the gut microbiome and bile acid levels as well as obesity and weight loss. [Read the full article here. ](https://www.fiercebiotech.com/medtech/sigrid-therapeutics-aims-to-ward-off-type-2-diabetes-edible-powdered-medical-device) ## Related articles - [I tried the alternative to the fat jab — did I lose weight?](https://sipore.com/insights/i-tried-the-alternative-to-the-fat-jab-did-i-lose-weight.md) — Media Coverage, 2024-10-23 - [How the new 'liquid Ozempic' helped me to scoff mt way through Christmas for 3 weeks and STILL lose weight](https://sipore.com/insights/daily-mail.md) — Media Coverage, 2023-12-28 ## How to cite SiPore Technologies (Sigrid Therapeutics AB). “Sigrid Therapeutics aims to ward off Type 2 diabetes with an edible, powdered medical device”. SiPore, 2019-10-24. https://sipore.com/insights/sigrid-therapeutics-aims-to-ward-off-type-2-diabetes-with-an-edible-powdered-med (accessed ). Use the trademarks as written: SiPore®, Carb Fence™. For the SHINE trial, cite the peer-reviewed publication in *eClinicalMedicine* (The Lancet Discovery Science, 2026) rather than this page. ## Company & contact - **Company:** SiPore Technologies — legal entity Sigrid Therapeutics AB (Swedish org.nr [556958-3023](https://www.allabolag.se/foretag/sigrid-therapeutics-ab/sundbyberg/forskning/2K3ZHRJI5YE3M)) - **Stockholm headquarters:** Vasagatan 14A, 172 61 Sundbyberg, Sweden ([map](https://www.google.com/maps/search/?api=1&query=Vasagatan%2014A%2C%20172%2061%20Sundbyberg%2C%20Sweden)) - **General enquiries:** [contact@sipore.com](mailto:contact@sipore.com) - **Partnerships & licensing:** [partnerships@sipore.com](mailto:partnerships@sipore.com) - **Origin:** Founded in Stockholm, Sweden - **Taglines:** “The meal companion for modern food.” · “Same meal. Less impact.” · “Scandinavian science. Global impact.” · “Precision science for the modern meal.” - **About:** SiPore® is a patented meal-companion technology designed to reduce the impact of modern meals at the level of digestion. **Our sites** — all sites owned and operated by Sigrid Therapeutics AB: - [SiPore.com](https://www.sipore.com/): Technology, science & partnerships - [SiPorePro.com](https://www.siporepro.com/): Practitioner products & professional resources - [SigridLife.com](https://sigridlife.com/): SIGRID consumer products - [SigridStabiliser.se](https://sigridstabiliser.se/): SIGRID Sweden --- [View on site](https://sipore.com/insights/sigrid-therapeutics-aims-to-ward-off-type-2-diabetes-with-an-edible-powdered-med) · [All insights](https://sipore.com/insights.md) · [Site index for agents (llms.txt)](https://sipore.com/llms.txt)